Printed from https://ideas.repec.org/s/spr/eujhec5.html
Content
May 2018, Volume 19, Issue 4
- 545-555 Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan
by Shota Saito & Motoi Azumi & Yusuke Muneoka & Katsuhiko Nishino & Takashi Ishikawa & Yuichi Sato & Shuji Terai & Kouhei Akazawa - 557-570 What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews
by Aureliano Paolo Finch & John Edward Brazier & Clara Mukuria - 571-584 Introduction of therapeutic reference pricing in Slovenia and its economic consequences
by Nika Marđetko & Mitja Kos - 585-594 The financial performance of the health care industry: a global, regional and industry specific empirical investigation
by Gregor Dorfleitner & Felix Rößle - 595-605 Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment
by Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin - 607-626 Autonomy and performance in the public sector: the experience of English NHS hospitals
by Rossella Verzulli & Rowena Jacobs & Maria Goddard - 627-636 Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
by Santiago Grau & Rafael Cámara & Manuel Jurado & Jaime Sanz & Belén Aragón & Irmina Gozalbo
April 2018, Volume 19, Issue 3
- 309-313 The triple challenge of mental health
by Peter Zweifel - 315-325 Emotions and scope effects in the monetary valuation of health
by María V. Avilés Blanco & Raúl Brey & Jorge Araña & José Luis Pinto Prades - 327-340 Economic and public health consequences of delayed access to medical care for migrants living with HIV in France
by Marlène Guillon & Michel Celse & Pierre-Yves Geoffard - 341-353 Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation
by Dirk Müller & Marion Danner & Kerstin Rhiem & Björn Stollenwerk & Christoph Engel & Linda Rasche & Lisa Borsi & Rita Schmutzler & Stephanie Stock - 355-367 The effectiveness of a population-based skin cancer screening program: evidence from Germany
by Micha Kaiser & Jörg Schiller & Christopher Schreckenberger - 369-383 Does socioeconomic status affect lengthy wait time in Canada? Evidence from Canadian Community Health Surveys
by Mohammad Hajizadeh - 385-408 Hospital heterogeneity: what drives the quality of health care
by Manhal Ali & Reza Salehnejad & Mohaimen Mansur - 409-417 Burden of suicide in Poland in 2012: how could it be measured and how big is it?
by Katarzyna Orlewska & Ewa Orlewska - 419-433 Using compensating variation to measure the costs of child disability in the UK
by Mariya Melnychuk & Francesca Solmi & Stephen Morris - 435-446 Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age
by Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög - 447-462 Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis
by Sofia Löfvendahl & Anna Jöud & Ingemar F. Petersson & Elke Theander & Åke Svensson & Katarina Steen Carlsson - 463-470 The socio-economic impact of work disability due to inflammatory bowel disease in Brazil
by Renata S. B. Fróes & Ana Teresa Pugas Carvalho & Antonio Jose V. Carneiro & Adriana Maria Hilu Barros Moreira & Jessica P. L. Moreira & Ronir R. Luiz & Heitor S. de Souza - 471-472 Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”
by Afschin Gandjour - 473-481 Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”
by Alexander Kuhlmann & J.-Matthias Graf Schulenburg
March 2018, Volume 19, Issue 2
- 173-175 The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
by Salah Ghabri & Josephine Mauskopf - 177-187 A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set
by Gareth Thomas - 189-201 The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach
by Grégoire Lagasnerie & Anne-Sophie Aguadé & Pierre Denis & Anne Fagot-Campagna & Christelle Gastaldi-Menager - 203-211 Improving risk equalization using information on physiotherapy diagnoses
by Frank Eijkenaar & René C. J. A. Vliet - 213-222 The impact of physician-level drug budgets on prescribing behavior
by Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt - 223-228 The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany
by Klaus Kaier & Holger Reinecke & Huseyin Naci & Lutz Frankenstein & Martin Bode & Werner Vach & Philip Hehn & Andreas Zirlik & Manfred Zehender & Jochen Reinöhl - 229-240 Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
by Michele R. Wilson & Annika Bergman & Helene Chevrou-Severac & Ross Selby & Michael Smyth & Matthew C. Kerrigan - 241-255 Systematic review of model-based economic evaluations of heart valve implantations
by Simone A. Huygens & Johanna. J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken - 257-266 Association between cultural distance and migrant self-rated health
by Jens Detollenaere & Stijn Baert & Sara Willems - 267-275 Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies
by Erik Nord - 277-291 New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year
by Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer - 293-307 Do healthcare tax credits help poor-health individuals on low incomes?
by Cinzia Di Novi & Anna Marenzi & Dino Rizzi
January 2018, Volume 19, Issue 1
- 1-4 Competition in pharmaceuticals: more product- than price-oriented?
by Livio Garattini & Anna Padula - 5-19 Competition and quality indicators in the health care sector: empirical evidence from the Dutch hospital sector
by R. R. Croes & Y. J. F. M. Krabbe-Alkemade & M. C. Mikkers - 21-35 A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
by Evelina A. Zimovetz & Alain Joseph & Rajeev Ayyagari & Josephine A. Mauskopf - 37-44 Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
by Umberto Restelli & Alfredo Alberti & Adriano Lazzarin & Marzia Bonfanti & Carmela Nappi & Davide Croce - 45-57 Investigating social inequalities in older adults’ dentition and the role of dental service use in 14 European countries
by Jing Shen & Stefan Listl - 59-73 Good jobs, good pay, better health? The effects of job quality on health among older European workers
by Golo Henseke - 75-86 A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations
by Felix Achana & Stavros Petrou & Kamran Khan & Amadou Gaye & Neena Modi - 87-102 Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial
by Bernhard Michalowsky & Steffen Flessa & Tilly Eichler & Johannes Hertel & Adina Dreier & Ina Zwingmann & Diana Wucherer & Henriette Rau & Jochen René Thyrian & Wolfgang Hoffmann - 103-121 A “healthy immigrant effect” or a “sick immigrant effect”? Selection and policies matter
by Amelie F. Constant & Teresa García-Muñoz & Shoshana Neuman & Tzahi Neuman - 123-152 Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
by Aris Angelis & Ansgar Lange & Panos Kanavos - 153-165 Corruption costs lives: evidence from a cross-country study
by Qiang Li & Lian An & Jing Xu & Mina Baliamoune-Lutz - 167-172 Patient preferences: a Trojan horse for evidence-based medicine?
by Afschin Gandjour
December 2017, Volume 18, Issue 9
- 1065-1067 Economic evaluation of personalized medicine: a call for real-world data
by Robert Terkola & Fernando Antoñanzas & Maarten Postma - 1069-1078 Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients
by Amaia Malet-Larrea & Estíbaliz Goyenechea & Miguel A. Gastelurrutia & Begoña Calvo & Victoria García-Cárdenas & Juan M. Cabases & Aránzazu Noain & Fernando Martínez-Martínez & Daniel Sabater-Hernández & Shalom I. Benrimoj - 1079-1093 Out-migration and attrition of physicians and dentists before and after EU accession (2003 and 2011): the case of Hungary
by Júlia Varga - 1095-1105 Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden
by Alessandra Ferrario - 1107-1123 Preferences for public involvement in health service decisions: a comparison between best-worst scaling and trio-wise stated preference elicitation techniques
by Seda Erdem & Danny Campbell - 1125-1135 Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data
by Katharina Bode & Rolf Vogel & Jochen Walker & Christoph Kröger - 1137-1156 Improving risk equalization with constrained regression
by Richard C. Kleef & Thomas G. McGuire & René C. J. A. Vliet & Wynand P. P. M. de Ven - 1157-1179 Gender-specific practice styles and ambulatory health care expenditures
by Boris Kaiser - 1181-1198 A methodological proposal to evaluate the cost of duration moral hazard in workplace accident insurance
by Ángel Martín-Román & Alfonso Moral
November 2017, Volume 18, Issue 8
- 933-936 Market approval for drugs in the EU: time to change direction?
by Alessandro Curto & Katelijne de Vooren & Livio Garattini - 937-965 The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies
by Alexandre Baptista & Inês Teixeira & Sónia Romano & António Vaz Carneiro & Julian Perelman - 967-977 Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale
by Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard - 979-986 Costs of dementia in the Czech Republic
by Iva Holmerová & Jakub Hort & Robert Rusina & Anders Wimo & Michal Šteffl - 987-1000 A method to simulate incentives for cost containment under various cost sharing designs: an application to a first-euro deductible and a doughnut hole
by D. Cattel & R. C. Kleef & R. C. J. A. Vliet - 1001-1011 Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies
by Hayley Bennett & Jason Gordon & Beverley Jones & Thomas Ward & Samantha Webster & Anupama Kalsekar & Yong Yuan & Michael Brenner & Phil McEwan - 1013-1030 Junior doctors’ medical specialty and practice location choice: simulating policies to overcome regional inequalities
by Pedro Ramos & Hélio Alves & Paulo Guimarães & Maria A. Ferreira - 1031-1039 The impact of minimum wages on population health: evidence from 24 OECD countries
by Otto Lenhart - 1041-1046 Cost effects of preterm birth: a comparison of health care costs associated with early preterm, late preterm, and full-term birth in the first 3 years after birth
by Josephine Jacob & Moritz Lehne & Andrea Mischker & Normen Klinger & Claudia Zickermann & Jochen Walker - 1047-1064 Switching gains and health plan price elasticities: 20 years of managed competition reforms in The Netherlands
by Rudy Douven & Katalin Katona & Frederik Schut & Victoria Shestalova
September 2017, Volume 18, Issue 7
- 801-803 On vaccination programs in the EU Member States: the case of the human papilloma virus
by Reyes Lorente & Fernando Antonanzas - 805-830 Healthier lifestyles after retirement in Europe? Evidence from SHARE
by Martina Celidoni & Vincenzo Rebba - 831-845 Measuring customer preferences in the German statutory health insurance
by Jonas B. Pendzialek & Dusan Simic & Stephanie Stock - 847-858 The social cost of chronic kidney disease in Italy
by Giuseppe Turchetti & S. Bellelli & M. Amato & S. Bianchi & P. Conti & A. Cupisti & V. Panichi & A. Rosati & F. Pizzarelli - 859-867 Does drug price-regulation affect healthcare expenditures?
by Omer Ben-Aharon & Oren Shavit & Racheli Magnezi - 869-882 Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort
by Dmitrij Achelrod & Jonas Schreyögg & Tom Stargardt - 883-892 The social cost of drugs in France in 2010
by Pierre Kopp & Marysia Ogrodnik - 893-904 Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
by Peter Greven & Vanja Sikirica & Yaozhu J. Chen & Tammy G. Curtice & Charles Makin - 905-919 The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program
by Anne Neumann & Lars Lindholm & Margareta Norberg & Olaf Schoffer & Stefanie J. Klug & Fredrik Norström - 921-932 Age effects in mortality risk valuation
by Raul Brey & Jose Luis Pinto-Prades
July 2017, Volume 18, Issue 6
- 667-670 The enigma of value: in search of affordable and accessible health care
by Thomas D. Szucs & Martina Weiss & Guido Klaus - 671-683 How important is severity for the evaluation of health services: new evidence using the relative social willingness to pay instrument
by Jeff Richardson & Angelo Iezzi & Aimee Maxwell - 685-696 Evaluating the consequences of rheumatoid arthritis
by Björn Sossong & Stefan Felder & Malte Wolff & Klaus Krüger - 697-701 A comparison of average wages with age-specific wages for assessing indirect productivity losses: analytic simplicity versus analytic precision
by Mark P. Connolly & Cole Tashjian & Nikolaos Kotsopoulos & Aomesh Bhatt & Maarten J. Postma - 703-713 The costs of hazardous alcohol consumption in Germany
by Tobias Effertz & Frank Verheyen & Roland Linder - 715-730 Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries
by Elena Nicod - 731-742 Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients
by L. T. Burgers & W. K. Redekop & M. J. Al & S. K. Lhachimi & N. Armstrong & S. Walker & C. Rothery & M. Westwood & J. L. Severens - 743-760 The impact of the design of payment scales on the willingness to pay for health gains
by Lotte Soeteman & Job Exel & Ana Bobinac - 761-771 Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK
by Diana Weidlich & Fredrik L. Andersson & Matthias Oelke & Marcus John Drake & Aino Fianu Jonasson & Julian F. Guest - 773-785 China’s medical savings accounts: an analysis of the price elasticity of demand for health care
by Hao Yu - 787-799 Waist circumference, body mass index, and employment outcomes
by Jonas Minet Kinge
June 2017, Volume 18, Issue 5
- 533-536 Access, use, and challenges of claims data analyses in Germany
by Sarah Neubauer & Kristine Kreis & Mike Klora & Jan Zeidler - 537-546 The impact of race, income, drug abuse and dependence on health insurance coverage among US adults
by Nianyang Wang & Xin Xie - 547-565 Healthcare inequality issues among immigrant elders after neoliberal welfare reform: empirical findings from the United States
by Younsook Yeo - 567-574 The dynamic relationship between health expenditure and economic growth: is the health-led growth hypothesis valid for Turkey?
by Emre Atilgan & Dilek Kilic & Hasan Murat Ertugrul - 575-585 Societal costs of fetal alcohol syndrome in Sweden
by Lisa Ericson & Lennart Magnusson & Bo Hovstadius - 587-608 Measuring the efficiency of large pharmaceutical companies: an industry analysis
by Fernando Gascón & Jesús Lozano & Borja Ponte & David Fuente - 609-621 Impact assessment of a pay-for-performance program on breast cancer screening in France using micro data
by Jonathan Sicsic & Carine Franc - 623-633 Cost analysis of whole genome sequencing in German clinical practice
by Marika Plöthner & Martin Frank & J.-Matthias Graf Schulenburg - 635-647 Measuring the productivity of residential long-term care in England: methods for quality adjustment and regional comparison
by Wei Yang & Julien Forder & Olena Nizalova - 649-665 The effects of organized screening programs on the demand for mammography in Switzerland
by Mark Pletscher
May 2017, Volume 18, Issue 4
- 399-404 A perspective on the health care expenditures for defensive medicine
by Michael Osti & Johannes Steyrer - 405-415 Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
by Fredrik Salvesen Haukaas & Trude Margrete Arnesen & Brita Askeland Winje & Eline Aas - 417-434 What happens to drinking when alcohol policy changes? A review of five natural experiments for alcohol taxes, prices, and availability
by Jon P. Nelson & Amy D. McNall - 435-447 Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey
by Alice Sanwald & Engelbert Theurl - 449-458 Economic impact of patients admitted to stroke units in Spain
by Jose Alvarez-Sabín & Manuel Quintana & Jaime Masjuan & Juan Oliva-Moreno & Javier Mar & Nuria Gonzalez-Rojas & Virginia Becerra & Covadonga Torres & María Yebenes - 459-469 A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events
by Anne-Line Couillerot-Peyrondet & Cléa Sambuc & Yoël Sainsaulieu & Cécile Couchoud & Isabelle Bongiovanni-Delarozière - 471-479 Economies of scale: body mass index and costs of cardiac surgery in Ontario, Canada
by Ana P. Johnson & Joel L. Parlow & Brian Milne & Marlo Whitehead & Jianfeng Xu & Susan Rohland & Joelle B. Thorpe - 481-494 Estimation of a physician practice cost function
by Lukas Kwietniewski & Mareike Heimeshoff & Jonas Schreyögg - 495-517 Frequency and intensity of alcohol consumption: new evidence from Sweden
by Gawain Heckley & Johan Jarl & Ulf-G Gerdtham - 519-531 Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece
by John N. Yfantopoulos & Athanasios E. Chantzaras
April 2017, Volume 18, Issue 3
- 269-272 Disruptive innovation and EU health policy
by Bengt Jönsson - 273-292 Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany
by Alexander Kuhlmann & J.-Matthias Graf Schulenburg - 351-360 Primary health care utilisation and its costs among middle-aged smokers
by Jaana Keto & Hanna Ventola & Jari Jokelainen & Markku Timonen & Kari Linden & Tero Ylisaukko-oja & Sirkka Keinänen-Kiukaanniemi & Juha Auvinen - 361-372 The impact of poor adult health on labor supply in the Russian Federation
by Yevgeniy Goryakin & Marc Suhrcke - 373-386 The role of time and risk preferences in adherence to physician advice on health behavior change
by Marjon Pol & Deirdre Hennessy & Braden Manns - 387-398 Analyzing disparity trends for health care insurance coverage among non-elderly adults in the US: evidence from the Behavioral Risk Factor Surveillance System, 1993–2009
by Shireen Assaf & Stefano Campostrini & Cinzia Di Novi & Fang Xu & Carol Gotway Crawford
March 2017, Volume 18, Issue 2
- 135-138 Competition in the healthcare sector: a missing dimension
by Peter Zweifel - 139-153 Competition in the Dutch hospital sector: an analysis of health care volume and cost
by Y. J. F. M. Krabbe-Alkemade & T. L. C. M. Groot & M. Lindeboom - 155-165 Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment
by Axel C. Mühlbacher & John F. P. Bridges & Susanne Bethge & Ch.-Markos Dintsios & Anja Schwalm & Andreas Gerber-Grote & Matthias Nübling - 167-180 How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence
by Wynand P. M. M. Ven & René C. J. A. Vliet & Richard C. Kleef - 181-193 Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
by Christine Blome & Matthias Augustin & Hidayet Metin & David Lohrberg - 195-208 Financial incentives, timing of births, and infant health: a closer look into the delivery room
by Hendrik Jürges - 209-226 A voluntary deductible in health insurance: the more years you opt for it, the lower your premium?
by K. P. M. Winssen & R. C. Kleef & W. P. M. M. Ven - 227-241 Assessing asthma severity based on claims data: a systematic review
by Christian Jacob & Jennifer S. Haas & Benno Bechtel & Peter Kardos & Sebastian Braun - 243-253 The cost of frailty in France
by Nicolas Sirven & Thomas Rapp - 255-267 Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort
by Han-I. Wang & Alexandra Smith & Eline Aas & Eve Roman & Simon Crouch & Cathy Burton & Russell Patmore
January 2017, Volume 18, Issue 1
- 1-5 Priorities in the Polish health care system
by Sylwia Nieszporska - 7-12 A short note on measuring subjective life expectancy: survival probabilities versus point estimates
by David R. Rappange & Job van Exel & Werner B. F. Brouwer - 13-31 The impact of a sick pay waiting period on sick leave patterns
by Catherine Pollak - 33-47 An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting
by L. B. Standfield & T. A. Comans & P. A. Scuffham - 49-58 Economic burden of toxicities associated with treating metastatic melanoma in eight countries
by Elizabeth Wehler & Zhongyun Zhao & S. Pinar Bilir & Julie Munakata & Beth Barber - 59-71 Why trash don’t pass? pharmaceutical licensing and safety performance of drugs
by Tannista Banerjee & Arnab Nayak - 73-82 Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
by Tomáš Mlčoch & Jiří Klimeš & Libor Fila & Věra Vávrová & Veronika Skalická & Marek Turnovec & Veronika Krulišová & Jitka Jirčíková & Dana Zemková & Klára Vilimovská Dědečková & Alena Bílková & Vladimíra Frühaufová & Lukáš Homola & Zuzana Friedmannová & Radovan Drnek & Pavel Dřevínek & Tomáš Doležal & Milan Macek - 83-96 Crisis, suicide and labour productivity losses in Spain
by Berta Rivera & Bruno Casal & Luis Currais - 97-117 Competition and quality in a physiotherapy market with fixed prices
by Piia Pekola & Ismo Linnosmaa & Hennamari Mikkola - 119-129 Medical ethics: enhanced or undermined by modes of payment?
by Peter Zweifel & Katharina Janus - 131-132 Commentary to: Medical ethics: enhanced or undermined by modes of payment?
by Friedrich Breyer - 133-134 Reply to commentary on: medical ethics: enhanced or undermined by modes of payment?
by Peter Zweifel & Katharina Janus
December 2016, Volume 17, Issue 9
- 1055-1058 Incentivizing research into the effectiveness of medical devices
by Michael Drummond & Rosanna Tarricone & Aleksandra Torbica - 1059-1072 Potential determinants of deductible uptake in health insurance: How to increase uptake in The Netherlands?
by K. P. M. Winssen & R. C. Kleef & W. P. M. M. Ven - 1073-1089 Does smoke cross the border? Cigarette tax avoidance in France
by Christian Ben Lakhdar & Nicolas Gérard Vaillant & François-Charles Wolff - 1091-1100 Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland
by Mark Fisher & Andrew Walker & Meritxell Falqués & Miguel Moya & Mark Rance & Douglas Taylor & Leandro Lindner - 1101-1115 The hidden economic burden of air pollution-related morbidity: evidence from the Aphekom project
by Olivier Chanel & Laura Perez & Nino Künzli & Sylvia Medina - 1117-1124 Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden
by J. Banefelt & S. Hallberg & K. M. Fox & J. Mesterton & C. J. Paoli & G. Johansson & L.-Å. Levin & P. Sobocki & S. R. Gandra - 1125-1140 What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences
by Axel Mühlbacher & Susanne Bethge - 1141-1158 The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective
by Tobias Effertz & Susanne Engel & Frank Verheyen & Roland Linder - 1159-1172 A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure
by F. Tomini & F. Prinzen & A. D. I. Asselt - 1173-1184 Exploring the determinants of endocrinologist visits by patients with diabetes
by Luiz Flavio Andrade & Thomas Rapp & Christine Sevilla-Dedieu
November 2016, Volume 17, Issue 8
- 923-926 Reimbursable drug classes and ceilings in Italy: why not only one?
by Livio Garattini & Alessandro Curto & Anna Padula - 927-938 Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results
by Theodoros Mantopoulos & Paul M. Mitchell & Nicky J. Welton & Richard McManus & Lazaros Andronis - 939-950 Multiple imputation strategies for zero-inflated cost data in economic evaluations: which method works best?
by Janet MacNeil Vroomen & Iris Eekhout & Marcel G. Dijkgraaf & Hein van Hout & Sophia E. de Rooij & Martijn W. Heymans & Judith E. Bosmans - 951-961 A cost analysis of orthopedic foot surgery: can outpatient continuous regional analgesia provide the same standard of care for postoperative pain control at home without shifting costs?
by Andrea Saporito & Stefano Calciolari & Laura Gonzalez Ortiz & Luciano Anselmi & Alain Borgeat & José Aguirre - 963-977 The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study
by Patrizio Armeni & Claudio Jommi & Monica Otto - 979-990 The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation
by Louis S. Matza & Kristina S. Boye & David H. Feeny & Lee Bowman & Joseph A. Johnston & Katie D. Stewart & Kelly McDaniel & Jessica Jordan - 991-999 Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach
by Elena Nicod & Timothy L. Jackson & Federico Grimaccia & Aris Angelis & Marc Costen & Richard Haynes & Edward Hughes & Edward Pringle & Hadi Zambarakji & Panos Kanavos - 1001-1010 Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
by Manel Mata-Cases & Marc Casajuana & Josep Franch-Nadal & Aina Casellas & Conxa Castell & Irene Vinagre & Dídac Mauricio & Bonaventura Bolíbar - 1011-1026 Is higher nursing home quality more costly?
by L. Di Giorgio & M. Filippini & G. Masiero - 1027-1040 The diffusion of generics after patent expiry in Germany
by Katharina Elisabeth Fischer & Tom Stargardt - 1041-1053 Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature
by David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson
September 2016, Volume 17, Issue 7
- 787-789 Improving health care systems by building ‘more Europe’
by F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas - 875-884 Multiple sclerosis: relapses, resource use, and costs
by A. J. Hawton & C. Green - 897-910 Marginal revenue and length of stay in inpatient psychiatry
by Mark Pletscher - 911-921 OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
by Nick Freemantle & Kristin Khalaf & Clara Loveman & Sanja Stanisic & Dmitry Gultyaev & Johanna Lister & Marcus Drake
July 2016, Volume 17, Issue 6
- 653-657 The demand for health insurance and behavioural economics
by K. P. M. van Winssen & R. C. van Kleef & W. P. M. M. van de Ven - 659-668 Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation
by Bernadette Li & John Cairns & James Fotheringham & Rommel Ravanan - 669-679 Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013
by Jennifer Haas & Sebastian Braun & Peter Wutzler - 681-691 Forecasting the use of elderly care: a static micro-simulation model
by Evelien Eggink & Isolde Woittiez & Michiel Ras - 693-709 Health, work and working conditions: a review of the European economic literature
by Thomas Barnay - 711-721 Health resource utilization associated with skeletal-related events: results from a retrospective European study
by Jean-Jacques Body & João Pereira & Harm Sleeboom & Nikos Maniadakis & Evangelos Terpos & Yves Pascal Acklin & Jindrich Finek & Oliver Gunther & Guy Hechmati & Tony Mossman & Luis Costa & Wojciech Rogowski & Hareth Nahi & Roger Moos - 723-732 The true impact of the French pay-for-performance program on physicians’ benzodiazepines prescription behavior
by Audrey Michel-Lepage & Bruno Ventelou - 733-744 Estimating informal care inputs associated with EQ-5D for use in economic evaluation
by Donna Rowen & Simon Dixon & Mónica Hernández-Alava & Clara Mukuria - 745-754 Expected 10-year treatment cost of breast cancer detected within and outside a public screening program in Norway
by Tron A. Moger & Gudrun M. W. Bjørnelv & Eline Aas - 755-770 Economic evaluation in chronic pain: a systematic review and de novo flexible economic model
by W. Sullivan & M. Hirst & S. Beard & D. Gladwell & F. Fagnani & J. López Bastida & C. Phillips & W. C. N. Dunlop - 771-785 Pay or conditions? The role of workplace characteristics in nurses’ labor supply
by Barbara Eberth & Robert F. Elliott & Diane Skåtun
June 2016, Volume 17, Issue 5
- 519-520 ‘Catastrophic’ healthcare expenditure: critique of a problematic concept and a proposal
by Peter Zweifel
May 2016, Volume 17, Issue 4
- 375-377 Prioritizing health services research: an economic perspective
by Afschin Gandjour
April 2016, Volume 17, Issue 3
- 229-233 Competition among health care providers: helpful or harmful?
by Pedro Pita Barros & Werner B. F. Brouwer & Sarah Thomson & Marco Varkevisser - 371-373 Erratum to: Treatment costs of attention deficit hyperactivity disorder in Germany
by Sebastian Braun & Jan Zeidler & Roland Linder & Susanne Engel & Frank Verheyen & Wolfgang Greiner
March 2016, Volume 17, Issue 2
- 113-116 Access to primary care in Italy: time for a shake-up?
by Livio Garattini & Alessandro Curto & Nick Freemantle - 117-127 Are some QALYs more equal than others?
by E. Wetering & N. Exel & J. Rose & R. Hoefman & W. Brouwer - 129-137 Economic hardship and suicide mortality in Finland, 1875–2010
by Marko Korhonen & Mikko Puhakka & Matti Viren - 139-147 The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach
by A. Marcellusi & R. Viti & A. Mecozzi & F. Mennini - 149-158 Willingness to pay for health insurance among the elderly population in Germany
by Jens-Oliver Bock & Dirk Heider & Herbert Matschinger & Hermann Brenner & Kai-Uwe Saum & Walter Haefeli & Hans-Helmut König - 159-170 Informal payments in the Greek health sector amid the financial crisis: old habits die last..
by Kyriakos Souliotis & Christina Golna & Yannis Tountas & Olga Siskou & Daphne Kaitelidou & Lycourgos Liaropoulos - 171-183 Do insurers respond to risk adjustment? A long-term, nationwide analysis from Switzerland
by Viktor von Wyl & Konstantin Beck - 185-193 Understanding the economic impact of intravascular ultrasound (IVUS)
by Alessandro Alberti & Pietro Giudice & Alessandra Gelera & Luca Stefanini & Virginia Priest & Michael Simmonds & Christa Lee & Matthew Wasserman - 195-201 Healthcare costs and resource utilization of asthma in Germany: a claims data analysis
by Christian Jacob & Benno Bechtel & Susanne Engel & Peter Kardos & Roland Linder & Sebastian Braun & Wolfgang Greiner - 203-215 Lessons from state mandates of preventive cancer screenings
by Wendy Xu & Bryan Dowd & Jean Abraham - 217-227 Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine
by Alexander Hirst & Chris Knight & Matt Hirst & Will Dunlop & Ron Akehurst
April 2016, Volume 17, Issue 1
- 1-5 Social/economic costs and health-related quality of life in patients with rare diseases in Europe
by Julio López-Bastida & Juan Oliva-Moreno & Renata Linertová & Pedro Serrano-Aguilar - 7-18 Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
by Karine Chevreul & Morgane Michel & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Márta Péntek & Johann Matthias Graf Schulenburg & Panos Kanavos & Ulf Persson & Giovani Fattore - 19-29 Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe
by Marianna Cavazza & Yllka Kodra & Patrizio Armeni & Marta Santis & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Márta Péntek & Johann Matthias Graf Schulenburg & Panos Kanavos & Karine Chevreul & Ulf Persson & Giovanni Fattore - 31-42 Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe
by Aris Angelis & Panos Kanavos & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Valentin Brodszky & Johann Matthias Graf Schulenburg & Karine Chevreul & Ulf Persson & Giovanni Fattore - 43-52 Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe
by Karine Chevreul & Coralie Gandré & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & László Gulácsi & Johann Matthias Graf Schulenburg & Panos Kanavos & Ulf Persson & Giovani Fattore - 53-65 Social/economic costs and quality of life in patients with haemophilia in Europe
by Marianna Cavazza & Yllka Kodra & Patrizio Armeni & Marta De Santis & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & László Gulácsi & Johann Matthias Graf Schulenburg & Panos Kanavos & Karine Chevreul & Ulf Persson & Giovanni Fattore - 67-78 Social/economic costs and health-related quality of life in patients with histiocytosis in Europe
by Georgi Iskrov & Itziar Astigarraga & Rumen Stefanov & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Arrigo Schieppati & Domenica Taruscio & Márta Péntek & Johann Matthias Graf Schulenburg & Panos Kanavos & Karine Chevreul & Ulf Persson & Giovanni Fattore - 79-87 Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe
by A. Kuhlmann & T. Schmidt & M. Treskova & J. López-Bastida & R. Linertová & J. Oliva-Moreno & P. Serrano-Aguilar & M. Posada-de-la-Paz & P. Kanavos & D. Taruscio & A. Schieppati & G. Iskrov & M. Péntek & C. Delgado & J. M. Schulenburg & U. Persson & K. Chevreul & G. Fattore - 89-98 Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
by Márta Péntek & László Gulácsi & Valentin Brodszky & Petra Baji & Imre Boncz & Gábor Pogány & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Georgi Iskrov & Arrigo Schieppati & Johann Matthias Graf Schulenburg & Panos Kanavos & Karine Chevreul & Ulf Persson & Giovanni Fattore - 99-108 Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe
by Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Manuel Posada-de-la-Paz & Pedro Serrano-Aguilar & Panos Kanavos & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Petra Baji & Claudia Delgado & Johann Matthias Graf Schulenburg & Ulf Persson & Karine Chevreul & Giovanni Fattore - 109-117 Social/economic costs and health-related quality of life in patients with scleroderma in Europe
by Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Panos Kanavos & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Márta Péntek & Claudia Delgado & Johann Mathias Schulenburg & Ulf Persson & Karine Chevreul & Giovanni Fattore
January 2016, Volume 17, Issue 1
- 1-4 Ebola fever epidemic 2014: a call for sustainable health and development policies
by Steffen Flessa & Michael Marx - 5-21 Differences in price elasticities of demand for health insurance: a systematic review
by Jonas Pendzialek & Dusan Simic & Stephanie Stock - 23-29 Is response to price equal for those with higher alcohol consumption?
by Joshua Byrnes & Anthony Shakeshaft & Dennis Petrie & Christopher Doran